JP5893561B2 - 新規ｎｐｒ−ｂアゴニスト - Google Patents

Info

Publication number

JP5893561B2

JP5893561B2 JP2012531012A JP2012531012A JP5893561B2 JP 5893561 B2 JP5893561 B2 JP 5893561B2 JP 2012531012 A JP2012531012 A JP 2012531012A JP 2012531012 A JP2012531012 A JP 2012531012A JP 5893561 B2 JP5893561 B2 JP 5893561B2

Authority

JP

Japan

Prior art keywords

alkyl

group

cnp

npr

amino acid

Prior art date

2009-09-25

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Fee Related

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000556 agonist Substances 0.000 title description 52
• 102100039341 Atrial natriuretic peptide receptor 2 Human genes 0.000 title description 2
• 101710102159 Atrial natriuretic peptide receptor 2 Proteins 0.000 title description 2
• 239000000203 mixture Substances 0.000 claims description 63
• 230000004410 intraocular pressure Effects 0.000 claims description 59
• 208000010412 Glaucoma Diseases 0.000 claims description 53
• 150000001875 compounds Chemical class 0.000 claims description 43
• 238000011282 treatment Methods 0.000 claims description 35
• 206010030043 Ocular hypertension Diseases 0.000 claims description 14
• 208000030533 eye disease Diseases 0.000 claims description 10
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
• 125000000217 alkyl group Chemical group 0.000 description 178
• 229910052739 hydrogen Inorganic materials 0.000 description 171
• 108010041801 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase Proteins 0.000 description 152
• 102100031478 C-type natriuretic peptide Human genes 0.000 description 152
• 229910052799 carbon Inorganic materials 0.000 description 109
• 210000004027 cell Anatomy 0.000 description 72
• 125000000623 heterocyclic group Chemical group 0.000 description 71
• 125000000753 cycloalkyl group Chemical group 0.000 description 61
• 125000003118 aryl group Chemical group 0.000 description 60
• 125000000539 amino acid group Chemical group 0.000 description 58
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 55
• 235000001014 amino acid Nutrition 0.000 description 51
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 49
• 108090000765 processed proteins & peptides Proteins 0.000 description 48
• 150000001413 amino acids Chemical class 0.000 description 47
• 108020001621 Natriuretic Peptide Proteins 0.000 description 45
• 102000004571 Natriuretic peptide Human genes 0.000 description 45
• 239000000692 natriuretic peptide Substances 0.000 description 45
• 238000000034 method Methods 0.000 description 44
• 101800001288 Atrial natriuretic factor Proteins 0.000 description 41
• 102400001282 Atrial natriuretic peptide Human genes 0.000 description 40
• 101800001890 Atrial natriuretic peptide Proteins 0.000 description 40
• 125000001072 heteroaryl group Chemical group 0.000 description 40
• 230000000694 effects Effects 0.000 description 34
• 201000010099 disease Diseases 0.000 description 32
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 31
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 30
• 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 30
• 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 30
• ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 30
• 210000001519 tissue Anatomy 0.000 description 30
• 125000001424 substituent group Chemical group 0.000 description 28
• 241000700159 Rattus Species 0.000 description 27
• -1 4-imidazoloyl Chemical group 0.000 description 26
• 102000004196 processed proteins & peptides Human genes 0.000 description 25
• 230000002829 reductive effect Effects 0.000 description 25
• 230000004913 activation Effects 0.000 description 24
• 235000008206 alpha-amino acids Nutrition 0.000 description 24
• 210000001508 eye Anatomy 0.000 description 24
• 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 23
• 101710102163 Atrial natriuretic peptide receptor 1 Proteins 0.000 description 23
• 238000004519 manufacturing process Methods 0.000 description 23
• 241000282414 Homo sapiens Species 0.000 description 22
• 230000001965 increasing effect Effects 0.000 description 22
• 102000005962 receptors Human genes 0.000 description 21
• 108020003175 receptors Proteins 0.000 description 21
• 239000003814 drug Substances 0.000 description 19
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 18
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 18
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 18
• 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 description 17
• 101710102157 Atrial natriuretic peptide receptor 3 Proteins 0.000 description 17
• 208000035475 disorder Diseases 0.000 description 17
• 210000003734 kidney Anatomy 0.000 description 17
• 206010016654 Fibrosis Diseases 0.000 description 16
• 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 16
• 108091008599 natriuretic peptide receptors Proteins 0.000 description 16
• 102000027424 natriuretic peptide receptors Human genes 0.000 description 16
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 14
• 241000699670 Mus sp. Species 0.000 description 14
• 230000015572 biosynthetic process Effects 0.000 description 14
• 210000001612 chondrocyte Anatomy 0.000 description 13
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 13
• 241000283973 Oryctolagus cuniculus Species 0.000 description 12
• 150000001576 beta-amino acids Chemical class 0.000 description 12
• 238000009472 formulation Methods 0.000 description 12
• 210000002216 heart Anatomy 0.000 description 12
• 230000001404 mediated effect Effects 0.000 description 12
• 210000000056 organ Anatomy 0.000 description 12
• 230000002265 prevention Effects 0.000 description 12
• 230000035755 proliferation Effects 0.000 description 12
• 230000000638 stimulation Effects 0.000 description 12
• 210000001585 trabecular meshwork Anatomy 0.000 description 12
• 230000008901 benefit Effects 0.000 description 11
• 210000000845 cartilage Anatomy 0.000 description 11
• 239000003795 chemical substances by application Substances 0.000 description 11
• 208000019425 cirrhosis of liver Diseases 0.000 description 11
• 239000002934 diuretic Substances 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 230000014509 gene expression Effects 0.000 description 11
• 230000012010 growth Effects 0.000 description 11
• 230000001976 improved effect Effects 0.000 description 11
• 238000001727 in vivo Methods 0.000 description 11
• 229910052760 oxygen Inorganic materials 0.000 description 11
• 239000000126 substance Substances 0.000 description 11
• 230000001225 therapeutic effect Effects 0.000 description 11
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
• 210000001742 aqueous humor Anatomy 0.000 description 10
• 206010012601 diabetes mellitus Diseases 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 230000004761 fibrosis Effects 0.000 description 10
• 125000005842 heteroatom Chemical group 0.000 description 10
• 238000000338 in vitro Methods 0.000 description 10
• 239000003446 ligand Substances 0.000 description 10
• 230000001452 natriuretic effect Effects 0.000 description 10
• 229910052757 nitrogen Inorganic materials 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 229910052717 sulfur Inorganic materials 0.000 description 10
• 238000003786 synthesis reaction Methods 0.000 description 10
• 201000004569 Blindness Diseases 0.000 description 9
• 206010020772 Hypertension Diseases 0.000 description 9
• 230000005856 abnormality Effects 0.000 description 9
• 230000001886 ciliary effect Effects 0.000 description 9
• 125000004122 cyclic group Chemical group 0.000 description 9
• 229940124597 therapeutic agent Drugs 0.000 description 9
• 150000001371 alpha-amino acids Chemical class 0.000 description 8
• 150000001412 amines Chemical class 0.000 description 8
• 210000001367 artery Anatomy 0.000 description 8
• 230000009286 beneficial effect Effects 0.000 description 8
• 230000008468 bone growth Effects 0.000 description 8
• 238000001802 infusion Methods 0.000 description 8
• 210000003584 mesangial cell Anatomy 0.000 description 8
• 239000003755 preservative agent Substances 0.000 description 8
• 108090000623 proteins and genes Proteins 0.000 description 8
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
• 206010013883 Dwarfism Diseases 0.000 description 7
• 108010078321 Guanylate Cyclase Proteins 0.000 description 7
• 102000014469 Guanylate cyclase Human genes 0.000 description 7
• 206010030348 Open-Angle Glaucoma Diseases 0.000 description 7
• 239000004480 active ingredient Substances 0.000 description 7
• 125000003275 alpha amino acid group Chemical group 0.000 description 7
• 230000004087 circulation Effects 0.000 description 7
• 230000007423 decrease Effects 0.000 description 7
• 230000036541 health Effects 0.000 description 7
• 230000002401 inhibitory effect Effects 0.000 description 7
• 239000011159 matrix material Substances 0.000 description 7
• 239000008194 pharmaceutical composition Substances 0.000 description 7
• 230000035935 pregnancy Effects 0.000 description 7
• 235000018102 proteins Nutrition 0.000 description 7
• 102000004169 proteins and genes Human genes 0.000 description 7
• 208000005069 pulmonary fibrosis Diseases 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 238000001356 surgical procedure Methods 0.000 description 7
• 208000024891 symptom Diseases 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• 150000007650 D alpha amino acids Chemical class 0.000 description 6
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
• 125000001931 aliphatic group Chemical group 0.000 description 6
• 125000002877 alkyl aryl group Chemical group 0.000 description 6
• 150000001602 bicycloalkyls Chemical group 0.000 description 6
• 210000000988 bone and bone Anatomy 0.000 description 6
• 230000000747 cardiac effect Effects 0.000 description 6
• 230000007882 cirrhosis Effects 0.000 description 6
• 125000004367 cycloalkylaryl group Chemical group 0.000 description 6
• 230000006378 damage Effects 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• 238000010790 dilution Methods 0.000 description 6
• 239000012895 dilution Substances 0.000 description 6
• 210000002744 extracellular matrix Anatomy 0.000 description 6
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
• 230000008595 infiltration Effects 0.000 description 6
• 238000001764 infiltration Methods 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 210000000265 leukocyte Anatomy 0.000 description 6
• 208000019423 liver disease Diseases 0.000 description 6
• 239000002609 medium Substances 0.000 description 6
• 210000001328 optic nerve Anatomy 0.000 description 6
• 230000002018 overexpression Effects 0.000 description 6
• 239000011347 resin Substances 0.000 description 6
• 229920005989 resin Polymers 0.000 description 6
• 239000002904 solvent Substances 0.000 description 6
• NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
• 230000004393 visual impairment Effects 0.000 description 6
• APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
• 201000001320 Atherosclerosis Diseases 0.000 description 5
• 101800000060 C-type natriuretic peptide Proteins 0.000 description 5
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 206010020880 Hypertrophy Diseases 0.000 description 5
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 210000004413 cardiac myocyte Anatomy 0.000 description 5
• 230000004663 cell proliferation Effects 0.000 description 5
• 210000000795 conjunctiva Anatomy 0.000 description 5
• 230000008602 contraction Effects 0.000 description 5
• 230000007812 deficiency Effects 0.000 description 5
• 230000010339 dilation Effects 0.000 description 5
• 230000035194 endochondral ossification Effects 0.000 description 5
• 210000002950 fibroblast Anatomy 0.000 description 5
• 238000001914 filtration Methods 0.000 description 5
• 210000004349 growth plate Anatomy 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 208000014674 injury Diseases 0.000 description 5
• 238000011068 loading method Methods 0.000 description 5
• 210000004072 lung Anatomy 0.000 description 5
• 108020004999 messenger RNA Proteins 0.000 description 5
• 210000002826 placenta Anatomy 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 150000003180 prostaglandins Chemical class 0.000 description 5
• 208000002815 pulmonary hypertension Diseases 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 239000011734 sodium Substances 0.000 description 5
• 229910052708 sodium Inorganic materials 0.000 description 5
• 230000009885 systemic effect Effects 0.000 description 5
• 210000002700 urine Anatomy 0.000 description 5
• 230000004382 visual function Effects 0.000 description 5
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 4
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
• 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 4
• 108010006654 Bleomycin Proteins 0.000 description 4
• 241000283690 Bos taurus Species 0.000 description 4
• 102000012421 C-Type Natriuretic Peptide Human genes 0.000 description 4
• 208000024172 Cardiovascular disease Diseases 0.000 description 4
• 102000008186 Collagen Human genes 0.000 description 4
• 108010035532 Collagen Proteins 0.000 description 4
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
• 206010048554 Endothelial dysfunction Diseases 0.000 description 4
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
• 206010019280 Heart failures Diseases 0.000 description 4
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 206010061323 Optic neuropathy Diseases 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 125000003342 alkenyl group Chemical group 0.000 description 4
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
• 125000004414 alkyl thio group Chemical group 0.000 description 4
• 125000000304 alkynyl group Chemical group 0.000 description 4
• 230000001028 anti-proliverative effect Effects 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 238000003149 assay kit Methods 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 229960001561 bleomycin Drugs 0.000 description 4
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 210000004556 brain Anatomy 0.000 description 4
• 150000001732 carboxylic acid derivatives Chemical group 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 101150017692 cnp gene Proteins 0.000 description 4
• 229920001436 collagen Polymers 0.000 description 4
• 210000004351 coronary vessel Anatomy 0.000 description 4
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 230000008694 endothelial dysfunction Effects 0.000 description 4
• 230000029142 excretion Effects 0.000 description 4
• 230000035558 fertility Effects 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 230000024924 glomerular filtration Effects 0.000 description 4
• 230000004217 heart function Effects 0.000 description 4
• 210000004024 hepatic stellate cell Anatomy 0.000 description 4
• 238000004128 high performance liquid chromatography Methods 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 238000005040 ion trap Methods 0.000 description 4
• 208000017169 kidney disease Diseases 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 210000005265 lung cell Anatomy 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 210000000651 myofibroblast Anatomy 0.000 description 4
• 210000000885 nephron Anatomy 0.000 description 4
• 208000020911 optic nerve disease Diseases 0.000 description 4
• 230000001575 pathological effect Effects 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• 230000010412 perfusion Effects 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 208000007232 portal hypertension Diseases 0.000 description 4
• 230000003389 potentiating effect Effects 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 230000002062 proliferating effect Effects 0.000 description 4
• 238000007634 remodeling Methods 0.000 description 4
• 230000008085 renal dysfunction Effects 0.000 description 4
• 201000002793 renal fibrosis Diseases 0.000 description 4
• 210000003994 retinal ganglion cell Anatomy 0.000 description 4
• 210000003786 sclera Anatomy 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 210000002460 smooth muscle Anatomy 0.000 description 4
• 150000003431 steroids Chemical group 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 210000001550 testis Anatomy 0.000 description 4
• 230000000699 topical effect Effects 0.000 description 4
• 230000002861 ventricular Effects 0.000 description 4
• 230000000007 visual effect Effects 0.000 description 4
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• 206010003445 Ascites Diseases 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 3
• 208000006029 Cardiomegaly Diseases 0.000 description 3
• 206010012565 Developmental glaucoma Diseases 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• 208000010228 Erectile Dysfunction Diseases 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 3
• 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• 206010018364 Glomerulonephritis Diseases 0.000 description 3
• 239000007821 HATU Substances 0.000 description 3
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
• 208000001953 Hypotension Diseases 0.000 description 3
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 3
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
• 208000019693 Lung disease Diseases 0.000 description 3
• 102000043136 MAP kinase family Human genes 0.000 description 3
• 108091054455 MAP kinase family Proteins 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• 206010067013 Normal tension glaucoma Diseases 0.000 description 3
• 208000004880 Polyuria Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 206010038389 Renal cancer Diseases 0.000 description 3
• 229920002125 Sokalan® Polymers 0.000 description 3
• 208000007536 Thrombosis Diseases 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 230000001746 atrial effect Effects 0.000 description 3
• 108010038664 atrial natriuretic factor receptor B Proteins 0.000 description 3
• 239000002876 beta blocker Substances 0.000 description 3
• 230000017531 blood circulation Effects 0.000 description 3
• 230000010478 bone regeneration Effects 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 210000001736 capillary Anatomy 0.000 description 3
• 230000009787 cardiac fibrosis Effects 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 210000004087 cornea Anatomy 0.000 description 3
• 210000005226 corpus cavernosum Anatomy 0.000 description 3
• 238000010511 deprotection reaction Methods 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
• 230000035619 diuresis Effects 0.000 description 3
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
• 210000003038 endothelium Anatomy 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 230000001434 glomerular Effects 0.000 description 3
• 239000003862 glucocorticoid Substances 0.000 description 3
• 201000011200 hepatorenal syndrome Diseases 0.000 description 3
• 201000001881 impotence Diseases 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 230000002427 irreversible effect Effects 0.000 description 3
• 238000011813 knockout mouse model Methods 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 201000002978 low tension glaucoma Diseases 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 238000010172 mouse model Methods 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 208000010125 myocardial infarction Diseases 0.000 description 3
• 210000000754 myometrium Anatomy 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 210000003733 optic disk Anatomy 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• 230000001991 pathophysiological effect Effects 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 239000002953 phosphate buffered saline Substances 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• 201000011461 pre-eclampsia Diseases 0.000 description 3
• 201000006366 primary open angle glaucoma Diseases 0.000 description 3
• 208000037821 progressive disease Diseases 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 235000002639 sodium chloride Nutrition 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 229960003604 testosterone Drugs 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• 210000004291 uterus Anatomy 0.000 description 3
• VPJXQGSRWJZDOB-UHFFFAOYSA-O 2-carbamoyloxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCOC(N)=O VPJXQGSRWJZDOB-UHFFFAOYSA-O 0.000 description 2
• WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
• 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
• 101800000457 CNP-22 Proteins 0.000 description 2
• 206010008723 Chondrodystrophy Diseases 0.000 description 2
• 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
• 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
• 206010018325 Congenital glaucomas Diseases 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
• 229930182566 Gentamicin Natural products 0.000 description 2
• 208000032612 Glial tumor Diseases 0.000 description 2
• 206010018338 Glioma Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102400001283 Long-acting natriuretic peptide Human genes 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 108010025020 Nerve Growth Factor Proteins 0.000 description 2
• 102000015336 Nerve Growth Factor Human genes 0.000 description 2
• 208000028389 Nerve injury Diseases 0.000 description 2
• 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
• 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
• 102000008212 P-Selectin Human genes 0.000 description 2
• 108010035766 P-Selectin Proteins 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 239000004372 Polyvinyl alcohol Substances 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 208000001647 Renal Insufficiency Diseases 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 208000017442 Retinal disease Diseases 0.000 description 2
• 206010057430 Retinal injury Diseases 0.000 description 2
• 206010038923 Retinopathy Diseases 0.000 description 2
• 208000034189 Sclerosis Diseases 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 208000008919 achondroplasia Diseases 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 239000000048 adrenergic agonist Substances 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 210000002159 anterior chamber Anatomy 0.000 description 2
• 230000002785 anti-thrombosis Effects 0.000 description 2
• 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 210000003433 aortic smooth muscle cell Anatomy 0.000 description 2
• 230000004509 aqueous humor production Effects 0.000 description 2
• 230000027746 artery morphogenesis Effects 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• 229960000686 benzalkonium chloride Drugs 0.000 description 2
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• 230000036770 blood supply Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 239000010839 body fluid Substances 0.000 description 2
• 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
• 239000006172 buffering agent Substances 0.000 description 2
• 229960004484 carbachol Drugs 0.000 description 2
• 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
• NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000003848 cartilage regeneration Effects 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
• 230000001447 compensatory effect Effects 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 239000003246 corticosteroid Substances 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 230000008021 deposition Effects 0.000 description 2
• 208000033679 diabetic kidney disease Diseases 0.000 description 2
• 239000010432 diamond Substances 0.000 description 2
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
• 239000006196 drop Substances 0.000 description 2
• 230000002526 effect on cardiovascular system Effects 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 238000001704 evaporation Methods 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 230000001605 fetal effect Effects 0.000 description 2
• 230000003176 fibrotic effect Effects 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229940014259 gelatin Drugs 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 229960002518 gentamicin Drugs 0.000 description 2
• 210000005086 glomerual capillary Anatomy 0.000 description 2
• 210000003878 glomerular mesangial cell Anatomy 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 239000001307 helium Substances 0.000 description 2
• 229910052734 helium Inorganic materials 0.000 description 2
• SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
• ZOCHHNOQQHDWHG-UHFFFAOYSA-N hexan-3-ol Chemical compound CCCC(O)CC ZOCHHNOQQHDWHG-UHFFFAOYSA-N 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• 229960001340 histamine Drugs 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 229960002591 hydroxyproline Drugs 0.000 description 2
• 208000021822 hypotensive Diseases 0.000 description 2
• 230000001077 hypotensive effect Effects 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 208000021267 infertility disease Diseases 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 201000006370 kidney failure Diseases 0.000 description 2
• 108020001756 ligand binding domains Proteins 0.000 description 2
• 208000018769 loss of vision Diseases 0.000 description 2
• 231100000864 loss of vision Toxicity 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 230000008774 maternal effect Effects 0.000 description 2
• 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
• 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 description 2
• QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 description 2
• 230000000877 morphologic effect Effects 0.000 description 2
• 210000000663 muscle cell Anatomy 0.000 description 2
• 230000008764 nerve damage Effects 0.000 description 2
• 229940053128 nerve growth factor Drugs 0.000 description 2
• 239000002736 nonionic surfactant Substances 0.000 description 2
• JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 2
• 229960004114 olopatadine Drugs 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 230000003076 paracrine Effects 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 230000018052 penile erection Effects 0.000 description 2
• 239000000813 peptide hormone Substances 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 239000002831 pharmacologic agent Substances 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 229920005862 polyol Polymers 0.000 description 2
• 150000003077 polyols Chemical class 0.000 description 2
• 229920002451 polyvinyl alcohol Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 238000002953 preparative HPLC Methods 0.000 description 2
• 230000002335 preservative effect Effects 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 230000004224 protection Effects 0.000 description 2
• 210000001147 pulmonary artery Anatomy 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 201000010174 renal carcinoma Diseases 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• 210000001525 retina Anatomy 0.000 description 2
• 238000005096 rolling process Methods 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 210000000582 semen Anatomy 0.000 description 2
• 238000013207 serial dilution Methods 0.000 description 2
• 230000009645 skeletal growth Effects 0.000 description 2
• 229960001922 sodium perborate Drugs 0.000 description 2
• YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 2
• 238000010532 solid phase synthesis reaction Methods 0.000 description 2
• 230000021595 spermatogenesis Effects 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
• 229960001052 streptozocin Drugs 0.000 description 2
• 230000035882 stress Effects 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 230000008719 thickening Effects 0.000 description 2
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
• 210000005239 tubule Anatomy 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 230000002485 urinary effect Effects 0.000 description 2
• 210000001186 vagus nerve Anatomy 0.000 description 2
• 210000001177 vas deferen Anatomy 0.000 description 2
• 208000019553 vascular disease Diseases 0.000 description 2
• 239000005526 vasoconstrictor agent Substances 0.000 description 2
• 230000000304 vasodilatating effect Effects 0.000 description 2
• 229940124549 vasodilator Drugs 0.000 description 2
• 239000003071 vasodilator agent Substances 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 230000004304 visual acuity Effects 0.000 description 2
• QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
• MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• MCKJPJYRCPANCC-XLXYOEISSA-N (8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(O)=O)[C@@H]4[C@@H]3CCC2=C1 MCKJPJYRCPANCC-XLXYOEISSA-N 0.000 description 1
• NWIUTZDMDHAVTP-KRWDZBQOSA-N (S)-betaxolol Chemical compound C1=CC(OC[C@@H](O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-KRWDZBQOSA-N 0.000 description 1
• TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
• WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
• JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
• BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 description 1
• VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
• DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
• XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
• FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
• JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
• 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 101710170757 Acidic leucine-rich nuclear phosphoprotein 32 family member A Proteins 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
• 241000024188 Andala Species 0.000 description 1
• YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 description 1
• 101100379125 Anguilla japonica npr2 gene Proteins 0.000 description 1
• 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 102100037293 Atrial natriuretic peptide-converting enzyme Human genes 0.000 description 1
• 101710133555 Atrial natriuretic peptide-converting enzyme Proteins 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical group OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• 101800000433 CNP-53 Proteins 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
• 206010007558 Cardiac failure chronic Diseases 0.000 description 1
• 206010007710 Cartilage injury Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 102000000018 Chemokine CCL2 Human genes 0.000 description 1
• GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 208000024304 Choroidal Effusions Diseases 0.000 description 1
• 206010008783 Choroidal detachment Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• 102000001189 Cyclic Peptides Human genes 0.000 description 1
• 108010069514 Cyclic Peptides Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 101710158332 Diuretic hormone Proteins 0.000 description 1
• 101710204261 Diuretic hormone class 2 Proteins 0.000 description 1
• ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
• 101710089384 Extracellular protease Proteins 0.000 description 1
• 206010015866 Extravasation Diseases 0.000 description 1
• 206010015943 Eye inflammation Diseases 0.000 description 1
• 206010015946 Eye irritation Diseases 0.000 description 1
• 206010015958 Eye pain Diseases 0.000 description 1
• 108091008794 FGF receptors Proteins 0.000 description 1
• 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
• 206010016803 Fluid overload Diseases 0.000 description 1
• UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 1
• 206010070531 Foetal growth restriction Diseases 0.000 description 1
• 102100035233 Furin Human genes 0.000 description 1
• 108090001126 Furin Proteins 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• 206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 1
• 208000022461 Glomerular disease Diseases 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 206010053759 Growth retardation Diseases 0.000 description 1
• 229920000569 Gum karaya Polymers 0.000 description 1
• 101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 description 1
• 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
• 101000780028 Homo sapiens Natriuretic peptides A Proteins 0.000 description 1
• 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 description 1
• 101000938391 Homo sapiens Transmembrane protein Proteins 0.000 description 1
• 206010020852 Hypertonia Diseases 0.000 description 1
• 206010021118 Hypotonia Diseases 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 101150008942 J gene Proteins 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 102100025136 Macrosialin Human genes 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102000055008 Matrilin Proteins Human genes 0.000 description 1
• 108010072582 Matrilin Proteins Proteins 0.000 description 1
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
• 229920000881 Modified starch Polymers 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 208000007379 Muscle Hypotonia Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
• 101150060710 NPR1 gene Proteins 0.000 description 1
• 101150066297 NPR3 gene Proteins 0.000 description 1
• 102400001263 NT-proBNP Human genes 0.000 description 1
• 102100034296 Natriuretic peptides A Human genes 0.000 description 1
• 101710187800 Natriuretic peptides A Proteins 0.000 description 1
• 102100036836 Natriuretic peptides B Human genes 0.000 description 1
• 101710187802 Natriuretic peptides B Proteins 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 108090000028 Neprilysin Proteins 0.000 description 1
• 102000003729 Neprilysin Human genes 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
• 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
• 208000022873 Ocular disease Diseases 0.000 description 1
• 101710089325 Osteocrin Proteins 0.000 description 1
• 102100040556 Osteocrin Human genes 0.000 description 1
• 108010058846 Ovalbumin Proteins 0.000 description 1
• 208000012868 Overgrowth Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920002413 Polyhexanide Polymers 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000005107 Premature Birth Diseases 0.000 description 1
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 101710118538 Protease Proteins 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
• 206010062237 Renal impairment Diseases 0.000 description 1
• QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
• 208000020221 Short stature Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• MKRNVBXERAPZOP-UHFFFAOYSA-N Starch acetate Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OC(C)=O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 MKRNVBXERAPZOP-UHFFFAOYSA-N 0.000 description 1
• 241000934878 Sterculia Species 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108010001957 Ularitide Proteins 0.000 description 1
• 102400001279 Urodilatin Human genes 0.000 description 1
• 208000032594 Vascular Remodeling Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 102400001284 Vessel dilator Human genes 0.000 description 1
• 101800001899 Vessel dilator Proteins 0.000 description 1
• 206010047513 Vision blurred Diseases 0.000 description 1
• 206010047555 Visual field defect Diseases 0.000 description 1
• 239000003875 Wang resin Substances 0.000 description 1
• NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
• 150000001241 acetals Chemical class 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 201000005180 acute myocarditis Diseases 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 239000003732 agents acting on the eye Substances 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 238000002266 amputation Methods 0.000 description 1
• 238000012435 analytical chromatography Methods 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 229960001232 anecortave Drugs 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 239000000043 antiallergic agent Substances 0.000 description 1
• 239000000030 antiglaucoma agent Substances 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940030600 antihypertensive agent Drugs 0.000 description 1
• 229960005475 antiinfective agent Drugs 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
• 229960002610 apraclonidine Drugs 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 230000002917 arthritic effect Effects 0.000 description 1
• 125000005418 aryl aryl group Chemical group 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 108010038647 atrial natriuretic factor receptor C Proteins 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 210000003050 axon Anatomy 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
• 229940073464 benzododecinium bromide Drugs 0.000 description 1
• 229960001574 benzoxonium chloride Drugs 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 229960002537 betamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
• 229960004324 betaxolol Drugs 0.000 description 1
• CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
• 229960002470 bimatoprost Drugs 0.000 description 1
• AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
• 208000002352 blister Diseases 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 229960003679 brimonidine Drugs 0.000 description 1
• 229960001724 brimonidine tartrate Drugs 0.000 description 1
• 230000007885 bronchoconstriction Effects 0.000 description 1
• 230000007883 bronchodilation Effects 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 210000005252 bulbus oculi Anatomy 0.000 description 1
• 239000004067 bulking agent Substances 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 210000004900 c-terminal fragment Anatomy 0.000 description 1
• 230000009460 calcium influx Effects 0.000 description 1
• 229960001631 carbomer Drugs 0.000 description 1
• 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
• 229940043234 carbomer-940 Drugs 0.000 description 1
• 229940031663 carbomer-974p Drugs 0.000 description 1
• 125000004432 carbon atom Chemical group C* 0.000 description 1
• 150000001735 carboxylic acids Chemical group 0.000 description 1
• 210000001054 cardiac fibroblast Anatomy 0.000 description 1
• 231100001011 cardiovascular lesion Toxicity 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 229920001525 carrageenan Polymers 0.000 description 1
• 229960001222 carteolol Drugs 0.000 description 1
• LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000011712 cell development Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000006727 cell loss Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
• 229960003260 chlorhexidine Drugs 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 239000000064 cholinergic agonist Substances 0.000 description 1
• 210000003161 choroid Anatomy 0.000 description 1
• 238000013375 chromatographic separation Methods 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 230000012085 chronic inflammatory response Effects 0.000 description 1
• 229960003405 ciprofloxacin Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 201000010897 colon adenocarcinoma Diseases 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000000306 component Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
• 229960000766 danazol Drugs 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000030609 dephosphorylation Effects 0.000 description 1
• 238000006209 dephosphorylation reaction Methods 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 238000000586 desensitisation Methods 0.000 description 1
• 238000003795 desorption Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229940119743 dextran 70 Drugs 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 229910003460 diamond Inorganic materials 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
• BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 230000001882 diuretic effect Effects 0.000 description 1
• CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
• 229940052760 dopamine agonists Drugs 0.000 description 1
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000005584 early death Effects 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 230000008753 endothelial function Effects 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000006353 environmental stress Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 210000005225 erectile tissue Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 235000019441 ethanol Nutrition 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical class C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000036251 extravasation Effects 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 231100000013 eye irritation Toxicity 0.000 description 1
• 210000000744 eyelid Anatomy 0.000 description 1
• 230000004438 eyesight Effects 0.000 description 1
• 206010016165 failure to thrive Diseases 0.000 description 1
• 210000001105 femoral artery Anatomy 0.000 description 1
• 230000004720 fertilization Effects 0.000 description 1
• 208000030941 fetal growth restriction Diseases 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 229960003469 flumetasone Drugs 0.000 description 1
• WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
• 229940043075 fluocinolone Drugs 0.000 description 1
• 210000000497 foam cell Anatomy 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 210000002592 gangliocyte Anatomy 0.000 description 1
• 230000027119 gastric acid secretion Effects 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 230000005283 ground state Effects 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 239000003966 growth inhibitor Substances 0.000 description 1
• 239000007952 growth promoter Substances 0.000 description 1
• 231100000001 growth retardation Toxicity 0.000 description 1
• 150000002357 guanidines Chemical class 0.000 description 1
• 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
• 238000011554 guinea pig model Methods 0.000 description 1
• 238000001631 haemodialysis Methods 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 210000002837 heart atrium Anatomy 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 230000000322 hemodialysis Effects 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 108091016204 human atrial natriuretic factor prohormone (1-30) Proteins 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 239000001341 hydroxy propyl starch Substances 0.000 description 1
• 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
• 210000003559 hypertrophic chondrocyte Anatomy 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 208000036260 idiopathic disease Diseases 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000000266 injurious effect Effects 0.000 description 1
• 230000000297 inotrophic effect Effects 0.000 description 1
• 230000010039 intracellular degradation Effects 0.000 description 1
• 230000008316 intracellular mechanism Effects 0.000 description 1
• 238000000185 intracerebroventricular administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 230000019948 ion homeostasis Effects 0.000 description 1
• 239000002563 ionic surfactant Substances 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000007803 itching Effects 0.000 description 1
• 210000004731 jugular vein Anatomy 0.000 description 1
• 235000010494 karaya gum Nutrition 0.000 description 1
• 239000000231 karaya gum Substances 0.000 description 1
• 229940039371 karaya gum Drugs 0.000 description 1
• 229960004752 ketorolac Drugs 0.000 description 1
• OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 208000037805 labour Diseases 0.000 description 1
• GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
• 229960001160 latanoprost Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
• 229960004771 levobetaxolol Drugs 0.000 description 1
• 210000002332 leydig cell Anatomy 0.000 description 1
• MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical group CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 231100001062 long bone abnormality Toxicity 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 229960001798 loteprednol Drugs 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 229960001810 meprednisone Drugs 0.000 description 1
• PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 229960001566 methyltestosterone Drugs 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 239000002395 mineralocorticoid Substances 0.000 description 1
• 230000003547 miosis Effects 0.000 description 1
• 239000003604 miotic agent Substances 0.000 description 1
• 235000019426 modified starch Nutrition 0.000 description 1
• 229960001664 mometasone Drugs 0.000 description 1
• QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 239000000472 muscarinic agonist Substances 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 210000001087 myotubule Anatomy 0.000 description 1
• WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
• 210000004898 n-terminal fragment Anatomy 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 201000003142 neovascular glaucoma Diseases 0.000 description 1
• HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 230000003227 neuromodulating effect Effects 0.000 description 1
• 239000002840 nitric oxide donor Substances 0.000 description 1
• VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 229940023490 ophthalmic product Drugs 0.000 description 1
• 210000004789 organ system Anatomy 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 229940092253 ovalbumin Drugs 0.000 description 1
• 230000027758 ovulation cycle Effects 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 210000001819 pancreatic juice Anatomy 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229960000292 pectin Drugs 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 230000036513 peripheral conductance Effects 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 238000011458 pharmacological treatment Methods 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 229940096826 phenylmercuric acetate Drugs 0.000 description 1
• 229960000247 phenylmercuric borate Drugs 0.000 description 1
• VUXSPDNLYQTOSY-UHFFFAOYSA-N phenylmercuric borate Chemical compound OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 description 1
• PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 150000003906 phosphoinositides Chemical class 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229960001416 pilocarpine Drugs 0.000 description 1
• 210000004560 pineal gland Anatomy 0.000 description 1
• 208000010916 pituitary tumor Diseases 0.000 description 1
• 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
• 239000004584 polyacrylic acid Substances 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229940068965 polysorbates Drugs 0.000 description 1
• 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
• 231100000857 poor renal function Toxicity 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229940069328 povidone Drugs 0.000 description 1
• 230000001376 precipitating effect Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• PXGPLTODNUVGFL-JZFBHDEDSA-N prostaglandin F2beta Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-JZFBHDEDSA-N 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• 150000007660 quinolones Chemical class 0.000 description 1
• 238000011555 rabbit model Methods 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000029865 regulation of blood pressure Effects 0.000 description 1
• 230000031337 regulation of inflammatory response Effects 0.000 description 1
• 230000023027 regulation of systemic arterial blood pressure by carotid body chemoreceptor signaling Effects 0.000 description 1
• 230000002040 relaxant effect Effects 0.000 description 1
• 230000004648 relaxation of smooth muscle Effects 0.000 description 1
• 230000008327 renal blood flow Effects 0.000 description 1
• 230000008663 renal system process Effects 0.000 description 1
• 210000005000 reproductive tract Anatomy 0.000 description 1
• 229960001487 rimexolone Drugs 0.000 description 1
• QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 102000014452 scavenger receptors Human genes 0.000 description 1
• 108010078070 scavenger receptors Proteins 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 230000000862 serotonergic effect Effects 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 201000005608 severe pre-eclampsia Diseases 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
• 229960002218 sodium chlorite Drugs 0.000 description 1
• 229940037001 sodium edetate Drugs 0.000 description 1
• 239000008279 sol Substances 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Chemical class 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000019100 sperm motility Effects 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 201000005428 steroid-induced glaucoma Diseases 0.000 description 1
• 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 150000003460 sulfonic acids Chemical group 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 229960004492 suprofen Drugs 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229960004906 thiomersal Drugs 0.000 description 1
• NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
• 229940103494 thiosalicylic acid Drugs 0.000 description 1
• 210000002303 tibia Anatomy 0.000 description 1
• 229960004605 timolol Drugs 0.000 description 1
• 229960005221 timolol maleate Drugs 0.000 description 1
• 230000008467 tissue growth Effects 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
• 229960000707 tobramycin Drugs 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 229940100613 topical solution Drugs 0.000 description 1
• 229940061102 topical suspension Drugs 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
• 229960002368 travoprost Drugs 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
• 229960005294 triamcinolone Drugs 0.000 description 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
• JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• IUCCYQIEZNQWRS-DWWHXVEHSA-N ularitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 IUCCYQIEZNQWRS-DWWHXVEHSA-N 0.000 description 1
• 238000000825 ultraviolet detection Methods 0.000 description 1
• 229960004317 unoprostone Drugs 0.000 description 1
• TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 230000006442 vascular tone Effects 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 230000001196 vasorelaxation Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 210000000264 venule Anatomy 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 239000003643 water by type Substances 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1